➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Colorcon
McKesson
Express Scripts
Merck

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

ANASTROZOLE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Anastrozole patents expire, and when can generic versions of Anastrozole launch?

Anastrozole is a drug marketed by Accord Hlthcare, Apotex Inc, Beijing Yiling, Cipla, Eugia Pharma, Fresenius Kabi Usa, Hikma, Impax Labs Inc, Kenton, Lannett Co Inc, Mylan, Natco Pharma Ltd, Neopharma, Sandoz, Sun Pharm Inds Ltd, Synthon Pharms, Teva Pharms, Watson Labs Teva, and Zydus Pharms Usa Inc. and is included in nineteen NDAs.

The generic ingredient in ANASTROZOLE is anastrozole. There are twenty-four drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the anastrozole profile page.

US ANDA Litigation and Generic Entry Outlook for Anastrozole

A generic version of ANASTROZOLE was approved as anastrozole by ACCORD HLTHCARE on June 28th, 2010.

  Start Trial

Drug patent expirations by year for ANASTROZOLE
Drug Prices for ANASTROZOLE

See drug prices for ANASTROZOLE

Drug Sales Revenue Trends for ANASTROZOLE

See drug sales revenues for ANASTROZOLE

Recent Clinical Trials for ANASTROZOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hoffmann-La RochePhase 2
Jonsson Comprehensive Cancer CenterPhase 2
The Affiliated Hospital of Qingdao UniversityPhase 1

See all ANASTROZOLE clinical trials

Pharmacology for ANASTROZOLE
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors

US Patents and Regulatory Information for ANASTROZOLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare ANASTROZOLE anastrozole TABLET;ORAL 090568-001 Jun 28, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva ANASTROZOLE anastrozole TABLET;ORAL 078984-001 Jun 28, 2010 DISCN No No   Start Trial   Start Trial   Start Trial
Hikma ANASTROZOLE anastrozole TABLET;ORAL 078485-001 Jun 28, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Cipla ANASTROZOLE anastrozole TABLET;ORAL 091164-001 Jun 28, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Natco Pharma Ltd ANASTROZOLE anastrozole TABLET;ORAL 079220-001 Jun 28, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Impax Labs Inc ANASTROZOLE anastrozole TABLET;ORAL 091242-001 May 31, 2012 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Merck
AstraZeneca
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.